Channel Therapeutics Corporation (CHRO)
AMEX: CHRO
· Real-Time Price · USD
1.35
0.09 (7.14%)
At close: Jul 01, 2025, 3:59 PM
7.14% (1D)
| Bid | 1.29 |
| Market Cap | 8.9M |
| Revenue (ttm) | 933.24K |
| Net Income (ttm) | -9.04M |
| EPS (ttm) | -12 |
| PE Ratio (ttm) | -0.1125 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.38 |
| Volume | 193,120 |
| Avg. Volume (20D) | 111,305 |
| Open | 1.25 |
| Previous Close | 1.26 |
| Day's Range | 1.23 - 1.48 |
| 52-Week Range | 1.23 - 54.29 |
| Beta | 3.29 |
About CHRO
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropath...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 16, 2024
Employees 4
Stock Exchange AMEX
Ticker Symbol CHRO
Website https://channeltherapeutics.com
2 months ago
+15.38%
Channel Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
4 months ago
+47.2%
Channel Therapeutics shares are trading higher after the company announced that it will combine with Ligand Subsidiary Pelthos Therapeutics to create a pain medicines focused entity.
1 year ago · seekingalpha.com
U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet WeekU.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week
